Donald L. Hagan LLC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 5.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,361 shares of the company’s stock after selling 514 shares during the period. Donald L. Hagan LLC’s holdings in Merck & Co., Inc. were worth $1,035,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in MRK. Vermillion & White Wealth Management Group LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $27,000. Bare Financial Services Inc bought a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Burkett Financial Services LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Rakuten Securities Inc. acquired a new stake in Merck & Co., Inc. in the fourth quarter worth about $30,000. Finally, RIA Advisory Group LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter worth about $30,000. Institutional investors own 76.07% of the company’s stock.
Merck & Co., Inc. Trading Up 0.3 %
MRK stock traded up $0.36 during mid-day trading on Friday, reaching $113.67. 10,102,341 shares of the stock traded hands, compared to its average volume of 8,717,050. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63. The company has a market cap of $287.90 billion, a P/E ratio of 126.30, a P/E/G ratio of 1.57 and a beta of 0.38. The stock’s fifty day moving average is $123.83 and its 200-day moving average is $126.09.
Merck & Co., Inc. Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date is Monday, September 16th. Merck & Co., Inc.’s dividend payout ratio is presently 342.22%.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday, June 18th. Argus raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Wolfe Research raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, July 31st. UBS Group reduced their price objective on shares of Merck & Co., Inc. from $148.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Truist Financial upped their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Buy” and a consensus target price of $134.58.
Read Our Latest Stock Analysis on Merck & Co., Inc.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More
- Five stocks we like better than Merck & Co., Inc.
- How to buy stock: A step-by-step guide for beginnersÂ
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Trading Stocks: RSI and Why it’s Useful
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What are earnings reports?
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.